分组1 - Pulmonx Corporation reported a quarterly loss of $0.34 per share, which was better than the Zacks Consensus Estimate of a loss of $0.40, representing an earnings surprise of +15.00% [1] - The company achieved revenues of $21.5 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 4.10% and showing an increase from $20.39 million year-over-year [2] - Over the last four quarters, Pulmonx has consistently surpassed consensus EPS and revenue estimates [2] 分组2 - The stock has underperformed significantly, losing about 69.2% since the beginning of the year, while the S&P 500 has gained 16.4% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $23.83 million, and for the current fiscal year, it is -$1.51 on revenues of $90.89 million [7] - The Medical Info Systems industry, to which Pulmonx belongs, is currently ranked in the top 20% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Insights - iBio, Inc. reported a quarterly loss of $0.11 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.07, marking an earnings surprise of -57.14% [1] - The company generated revenues of $0.1 million for the quarter ended September 2025, consistent with the Zacks Consensus Estimate, compared to zero revenues a year ago [2] - iBio shares have declined approximately 49.4% year-to-date, contrasting with the S&P 500's gain of 16.4% [3] Company Performance - Over the last four quarters, iBio has exceeded consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $0.1 million, and for the current fiscal year, it is -$0.40 on revenues of $0.5 million [7] - The estimate revisions trend for iBio was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which iBio belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Lucid Diagnostics Inc. reported a quarterly loss of $0.1 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, marking an earnings surprise of -66.67% [1] - The company generated revenues of $1.21 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 6.85% and showing a slight increase from $1.17 million a year ago [2] - The stock has increased approximately 27% since the beginning of the year, outperforming the S&P 500's gain of 16.4% [3] Financial Performance - Over the last four quarters, Lucid Diagnostics has not surpassed consensus EPS estimates, with the current consensus EPS estimate for the upcoming quarter at -$0.07 and for the current fiscal year at -$0.35 [2][7] - The company has topped consensus revenue estimates only once in the last four quarters [2] Market Outlook - The earnings outlook and estimate revisions trend for Lucid Diagnostics were favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The Medical - Instruments industry, to which Lucid Diagnostics belongs, is currently in the top 29% of Zacks industries, suggesting a positive industry outlook [8]

Core Insights - Astria Therapeutics reported a quarterly loss of $0.55 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.41, marking an earnings surprise of -34.15% [1] - The company generated revenues of $0.71 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 95.59%, compared to zero revenues a year ago [2] - The stock has increased approximately 39.9% year-to-date, outperforming the S&P 500's gain of 16.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.59 on $2 million in revenues, and for the current fiscal year, it is -$2.09 on $17 million in revenues [7] - The estimate revisions trend for Astria Therapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Astria Therapeutics belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Aytu BioPharma Inc., another company in the same industry, is expected to report a quarterly loss of $0.06 per share, reflecting a year-over-year change of +70% [9]

Core Insights - Creative Realities, Inc. reported a quarterly loss of $0.32 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.08, marking an earnings surprise of -300.00% [1] - The company's revenues for the quarter ended September 2025 were $10.55 million, missing the Zacks Consensus Estimate by 19.18%, and down from $14.44 million a year ago [2] - The stock has gained approximately 13.9% year-to-date, underperforming the S&P 500's gain of 16.4% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is breakeven on revenues of $16.25 million, while for the current fiscal year, it is $0.07 on revenues of $52.06 million [7] Estimate Revisions - Prior to the earnings release, the trend for estimate revisions was unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] Industry Context - The Internet - Software industry, to which Creative Realities, Inc. belongs, is currently ranked in the top 24% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Core Insights - BioXcel Therapeutics, Inc. reported a quarterly loss of $2.18 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.54, representing an earnings surprise of -41.56% [1] - The company generated revenues of $0.1 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 34.67% and down from $0.21 million a year ago [2] - BioXcel shares have declined approximately 66.2% year-to-date, contrasting with the S&P 500's gain of 16.4% [3] Financial Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.82 on revenues of $0.2 million, while for the current fiscal year, it is -$6.93 on revenues of $0.64 million [7] Market Outlook - The earnings outlook and estimate revisions will significantly influence the stock's immediate price movement [3][4] - The Zacks Rank for BioXcel is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] - The Medical - Biomedical and Genetics industry is ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - Stereotaxis Inc. reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of $0.06, marking a 50% earnings surprise [1] - The company generated revenues of $7.46 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 13.21% and down from $9.2 million a year ago [2] - Stereotaxis shares have increased by approximately 22.4% year-to-date, outperforming the S&P 500's gain of 16.2% [3] Earnings Outlook - The earnings outlook for Stereotaxis is crucial for investors, with current consensus EPS estimates at -$0.06 for the next quarter and -$0.23 for the current fiscal year [7] - The company holds a Zacks Rank 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Stereotaxis belongs, is currently in the top 25% of Zacks industries, suggesting a favorable environment for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

分组1 - Hallador Energy reported quarterly earnings of $0.55 per share, significantly exceeding the Zacks Consensus Estimate of $0.06 per share, representing an earnings surprise of +816.67% [1] - The company achieved revenues of $146.85 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 27.42%, compared to $105.04 million in the same quarter last year [2] - Hallador Energy has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] 分组2 - The stock has increased approximately 71.8% since the beginning of the year, outperforming the S&P 500's gain of 14.4% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $0.04 for the upcoming quarter and $0.53 for the current fiscal year [4][7] - The Zacks Industry Rank indicates that the Alternative Energy - Other sector is currently in the bottom 36% of over 250 Zacks industries, which may impact Hallador Energy's stock performance [8]

Core Insights - FibroGen reported a quarterly loss of $1.61 per share, significantly better than the Zacks Consensus Estimate of a loss of $4.01, marking an earnings surprise of +59.85% [1] - The company's revenues for the quarter were $1.08 million, missing the Zacks Consensus Estimate by 34.39%, and a substantial decline from $46.33 million in the same quarter last year [2] - FibroGen shares have underperformed the market, losing about 16.7% year-to-date compared to the S&P 500's gain of 14.4% [3] Financial Performance - Over the last four quarters, FibroGen has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$4.17 on revenues of $1.67 million, and for the current fiscal year, it is -$5.59 on revenues of $6.85 million [7] Market Outlook - The sustainability of FibroGen's stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The Zacks Rank for FibroGen is currently 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Drugs industry, to which FibroGen belongs, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact FibroGen's performance [5]

Exodus Movement, Inc. (EXOD) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +5,400.00%. A quarter ago, it was expected that this company would post a loss of $0.08 per share when it actually produced earnings of $1.12, delivering a surprise of +1500%.Over the last four quar ...